As per our report, the size of the global diabetes devices market is estimated to be worth USD 28.60 billion by 2027 and USD 21.58 billion in 2022, growing at a CAGR of 5.79% during the forecast period.
Diabetes devices help know the sugar levels and take appropriate measures to manage blood sugar levels. These devices decrease the burden on the patient who has diabetes and improves the quality of life. According to the International Diabetes Federation (IDF), in 2015, the number of diabetes patients is 414 million, whereas it raised to 425 million in 2017. Also, the report stated that around 1.6 million people were dead due to diabetes in 2016. The government organizations are planning to give proper access to diabetes care devices in healthcare sectors, especially in rural areas, to minimize the risk of diabetes.
MARKET DRIVERS
The growing prevalence of diabetes worldwide and the increasing need for safety measures are majorly driving the global diabetes devices market growth.
The rapid increase in the incidence of diabetes due to urbanization and sedentary lifestyles is a crucial factor in the growth of the diabetes devices market. The World Health Organization (WHO) predicts that diabetes is one of the leading causes of death. As the number of patients with diabetes increased, the demand for diabetes treatment devices also did. In addition, the need for quick and effective diagnostic methods has also contributed to the growth of the diabetes devices market.
It is expected that market growth will be accelerated further due to rapid technological advances in diabetes, the increase in the population of obesity, the increase in the consumption of junk food, and the fast diagnosis and treatment of diabetes.
Additionally, the elderly population is very vulnerable to diabetes due to unhealthy eating and sedentary lifestyles. It has led to increased demand for diabetes care devices and accelerated market growth in the recent past. As knowledge of diabetes management has increased, the market growth of diabetes management devices has accelerated. The widespread advances in health infrastructures and economic development have benefited the market.
Some governments are planning to provide optimal diabetes treatment at a low cost. Many companies also focus on minimizing the cost of diabetes management devices, which is estimated to favor the global diabetes devices market growth. It is also expected that increased awareness of diabetes monitoring devices and untapped market opportunities in developing countries provides numerous opportunities for diabetes devices market growth in this vicinity.
MARKET RESTRAINTS
Less awareness regarding the usage and benefits of these devices in underdeveloped countries is majorly hindering the global diabetes devices market growth. In addition, the long process of registration and reimbursement problems also poses a threat to the market. Further, the diabetes devices market is restricted by the high costs of diagnosis and treatment. Moreover, reimbursement issues and patent expiry are also an issue. The diabetes devices offer a solution for diabetes patients to manage glucose in the blood.
COVID-19 Impact on the global diabetes devices market:
COVID-19 is a worldwide public health emergency, affecting almost every sector. During the COVID-19 pandemic, the FDA provided guidelines to increase the availability and capability of non-invasive remote tracking systems, such as continuous glucose monitors (CGM). In addition, the COVID-19 pandemic has increased the need to evaluate the effectiveness of CGM in hospitals to conserve personal protective equipment (PPE) and limit the exposure of healthcare workers. Diabetes is a chronic condition characterized by the pancreas' failure to contain enough insulin or the body's inability to use the insulin it produces effectively.
Due to insulin production, diabetes devices are often used to determine blood sugar levels in the body. Diabetic patients are given care to accurately control their blood glucose levels and improve their recovery from this chronic condition. Care providers and patients constantly use diabetic care devices to check blood glucose levels regularly. The increase is primarily due to the COVID-19 epidemic, which puts diabetes at a higher risk of severe illness. Diabetic patients are also more susceptible to coronavirus infection. As a result, rising COVID-19 cases are expected to accelerate the development of diabetes care devices.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Covered |
By Type and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This research report on the global diabetes devices market has been segmented based on the type and region.
Diabetes Devices Market - By Type:
Based on type, the market is led by glucose monitoring devices. Increasing the prevalence of effective diabetes management procedures in hospitals and clinics is lavishing the market's growth rate. Growing awareness of monitoring glucose levels regularly is also one of the factors dominating the market shares. Shifting trends towards self-medication and a rise in the demand for point-of-care testing devices are accelerating the growth rate of the diabetes devices market. Initiative steps by the government by increasing campaign programs, especially in rural areas, are promoting the market's growth to the extent. The insulin delivery systems segment is expected to have the highest CAGR in the coming years to improve diagnostic procedures with different systems. Also, people demand effective and faster methods enhance the market's growth. Minimally invasive treatment procedures are also a part of treating diabetes, fueling the market's growth.
Most sales of diabetes devices worldwide happen to disposable pens, insulin pumps, and blood glucose test strips. These devices represent approximately 60% of the global market share. In the European market for diabetes medications, 21.03% of the income is contributed from the blood glucose strain insulin pump projected to grow at 5.06% CAGR from 2019 to 2024. The use of insulin pumps has increased in Europe over the years. However, the low frequency of insulin pumps in Europe is due to the lack of diabetic patients' awareness.
Diabetes Devices Market - By Region:
Based on the region, the diabetes devices market in North America held the largest share in the global diabetes care products. However, over the past few years, with the exponential increase in the cost related to Diabetes, cost-efficient pen needle development will significantly impact the market for diabetes care devices in North America in the years ahead.
In Europe, the market is driven by a sudden rise in the number of people affected with Diabetes and high investments in R & D. Also, with increasing awareness among the patients, there is quite a hike in demand for diabetes care devices.
The diabetes devices market in Europe is driven by a sudden rise in the number of people affected with Diabetes and high investments in R & D. Also, with increasing awareness among the patients, there is quite a hike in demand for diabetes care devices.
The diabetes devices market in the APAC region has many opportunities. Europe and Asia-Pacific follow North America’s way. China (1.3 billion) and India (1.2 billion), the most populous countries in this region, contribute to the demand for diabetes care devices. According to the International Diabetes Federation, China had the most significant diabetic patients, with around 96.2 million, and India had about 66.8 million diabetic patients. As of 2019, approximately 45% of the global diabetic population is from China and India. This is because many global diabetes care device companies are interested in investing in these countries.
The Diabetes Devices Market in Latin America has been estimated at USD 2.00 billion in 2021 and is projected to reach USD 2.74 billion by 2026, at a CAGR of 6.47% during the forecast period from 2021 to 2026.
The diabetes devices market in the Middle East & Africa is majorly driven by the rising awareness about disease care and the increasing incidence of chronic diseases. The Middle East and North Africa currently witness 35.4million people affected with Diabetes, which will reach 72.1 million by 2040. The rest of the African region witnesses 14.2 million people affected with diabetes, which is said to reach 34.2 million by 2040.
KEY MARKET PARTICIPANTS:
The most promising companies dominating the global diabetes devices market profiled in this report are Roche Diagnostics, Johnson & Johnson, LifeScan, Inc. and Animas Inc., Becton-Dickinson, Novo Nordisk, Bayer AG, Abbott Laboratories, Ypsomed AG, Medtronic plc, Insulet Inc., Terumo Corporation, Tandem Diabetes Care, Inc. and Dexcom, Inc. (U.S.).
RECENT MARKET DEVELOPMENTS:
Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
Market Segmentation
5.1 Global Diabetes Care Devices Market, by Type
5.1.1 Glucose Monitoring Devices
5.1.1.1 Self Blood Glucose Monitoring Devices
5.1.1.1.1 Glucose Meters
5.1.1.1.2 Test strips
5.1.1.1.3 Lancets
5.1.1.1.4 Hemoglobin A1C testing Kits
5.1.1.2 Continous Glucose Monitoring Devices
5.1.2 Insulin Delivery Systems
5.1.2.1 Insulin Syringes
5.1.2.2 Insulin Pens
5.1.2.3 Insulin Pumps
5.1.2.4 Jet Injectors
5.1.3 Control Solutions
Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.2.7 Switzerland
6.2.8 Russia
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
Market Leaders' Analysis
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic Inc.
8.3 Johnson & Johnson
8.4 Abbott Laboratories
8.5 Becton, Dickinson and Company
8.6 Ascensia Diabetes care
8.7 Novo Nordisk A/S
8.8 Dexcom, Inc.
8.9 Insulet Corporation
8.10 Terumo Corporation
8.11 Tandem Diabetes Care, Inc
8.12 Ypsomed AG
Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
11. Appendix
List of Tables
List of Figures
FAQ's
The global market size for diabetes devices was worth USD 21.58 billion in 2022 and is forecasted to reach USD 28.6 billion by 2027.
Based on type, the glucose monitoring devices segment accounted for a dominating share in the global diabetes devices market in 2022.
Geographically, the APAC region is projected to experience numerous growth opportunities and also witness the fastest CAGR in the global diabetes devices market.
Roche Diagnostics, Johnson & Johnson, LifeScan, Inc. and Animas Inc., Becton-Dickinson, Novo Nordisk, Bayer AG, Abbott Laboratories, Ypsomed AG, Medtronic plc, Insulet Inc., Terumo Corporation, Tandem Diabetes Care, Inc. and Dexcom, Inc. (U.S.) are a few of the notable players in the global diabetes devices market.
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
